Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163514
Status:
COMPLETED
Last Update Posted:
2016-12-02
First Post:
2005-09-12
Brief Title:
Safety and Effectiveness of Ciclesonide Nasal Spray in Children 6 to 11 Years With Perennial Allergic Rhinitis BY9010M1-403
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels 200 Mcg 100 Mcg or 25 Mcg Once Daily in the Treatment of Perennial Allergic Rhinitis PAR in Patients 6-11 Years of Age
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo inactive substance nasal spray in relieving symptoms of perennial allergic rhinitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None